Format

Send to:

Choose Destination
See comment in PubMed Commons below
Int J Nephrol Renovasc Dis. 2012;5:97-100. doi: 10.2147/IJNRD.S30194. Epub 2012 Jun 15.

Thrombotic microangiopathy associated with use of interferon-beta.

Author information

  • 1Department of Nephrology, Hospital Universitario La Paz, Madrid, Spain.

Abstract

Interferon-beta is widely used for the treatment of relapsing multiple sclerosis. The drug is usually well tolerated, but autoimmune adverse effects, including kidney disease, have been reported. Only a few cases of hemolytic uremic syndrome-thrombotic microangiopathy associated interferon-alpha have been described so far, and even fewer with beta-interferon. We report a patient who developed thrombotic microangiopathy during treatment with interferon-beta and improved after discontinuation and steroid therapy. Complement cascade and antiphospholipid antibodies are investigated. The spectrum of renal diseases associated with interferon-beta treatment is also reviewed.

KEYWORDS:

interferon-beta; multiple sclerosis; thrombotic microangiopathy hemolytic uremic syndrome

PMID:
22815645
[PubMed]
PMCID:
PMC3399315
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk